Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. scPharmaceuticals Inc.
CRL
•scPharmaceuticals Inc.

scPharmaceuticals Inc. – FDA CRL

Record Details

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to scPharmaceuticals Services, Inc. for their New Drug Application (NDA 209988) concerning Furoscix

(Furosemide), an 80 mg/10 mL drug-device combination product. This action followed the company's June 30, 2020, resubmission. The FDA determined the application could not be approved due to several critical issues related to the device component and labeling, under the regulatory framework of Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

Key violations included significant, uncommunicated design changes to the device during the review cycle, which raised concerns about safety and efficacy. The agency also identified outstanding deficiencies in the Master Access File supporting the device constituent and noted issues with biocompatibility testing, particularly regarding differences between test articles and the final product, and inadequate particulate matter analysis. Chemical characterization of leachables lacked clarity on clinically relevant testing conditions and methods for detecting specific compounds. Furthermore, the product labeling was deemed insufficient, failing to provide adequate electrical safety and electromagnetic compatibility (EMC) information as per IEC 60601-1 series, and did not incorporate previously requested warnings on various hazards and essential performance information.

Required actions include submitting the finalized, to-be-marketed device design with comprehensive supporting documentation, resolving all Master Access File deficiencies, conducting appropriate biocompatibility and leachable testing under clinically relevant conditions, and thoroughly revising the product labeling to comply with all specified regulatory standards and guidance documents.

Company
scPharmaceuticals Inc.
Product type
Drugs
Office
Division of Cardiology and Nephology
Person
  • Eric Kendig, PhD
View Company Profile

ID · 9323c1fe-a63e-454a-87cf-4a6103e0f7c0

Other documents for scPharmaceuticals Inc.
  • 483 - 2024-01-25January 25, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore scPharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.